**BIOGEN 105MS401 (POP)**

Plegridy (PEGINTERFERON β-1A) REAL WORLD EFFECTIVENESS AND SAFETY OBSERVATIONAL PROGRAM

**ACORDA (DALF-PS-1016)**

A DOUBLE BLIND, PLACEBO CONTROLLED, PARALEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE STRENGHTS OF DALFAMPRIDINE EXTENDED RELEASE TABLETS FOR TREATMENT OF STABLE WALKING DEFICITS IN POST-ISCHEMIC STROKE (MILESTONE)

**BIOGEN 109MS404 (RESPOND)**

A MULTICENTER,OPEN-LABEL,12-MONTH OBSERVATIONAL STUDY EVALUATING THE CLINICAL EFFECTIVENESS AND IMPACT ON PATIENT-REPORTED OUTCOMES OF ORAL TECFIDERA (DIMETHYL FUMARATE) DELAYED RELEASE CAPSULES IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS AFTER SUBOPTIMAL RESPONSE TO GLATIRAMER ACETATE

**BIOGEN (ESTEEM)**

A MULTICENTER, GLOBAL, OBSERVATIONAL STUDY TO COLLECT INFORMATION ON SAFETY AND TO DOCUMENT THE DRUG UTILIZATION OF TECFIDERA (DIMETHYL FUMARATE) WHEN USED IN ROUTINE MEDICAL PRACTICE IN THE TREATMENT OF MULTIPLE SCLEROSIS

**LABRYS BIOLOGICS**

A MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED PARALLEL-GROUP,STUDY COMPARING THE EFFICACY AND SAFETY OF TWO DOSES OF SUBCUTANEOUS LBR-101 WITH PLACEBO FOR THE PREVENTATIVE TREATMENT OF HIGH FREQUENCY EPISODIC MIGRAINE

**LABRYS BIOLOGICS**

A MULTICENTER, DOUBLE-BLIND, DOUBLE DUMMY, PLACEBO CONTROLLED PARALLEL-GROUP,MULTI-DOSE STUDY COMPARING THE EFFICACY AND SAFETY OF TWO DOSES OF SUBCUTANEOUS LBR-101 WITH PLACEBO FOR THE PREVENTATIVE TREATMENT OF CHRONIC MIGRAINE

**AVANIR PHARMACEUTICALS,INC**

A STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFECTIVENESSOF NEUDEXTA (DEXTROMETHORPHAN 20MG/QUINIDINE 10MG) IN THE TREATMENT OF PSEUDOBULBAR AFFECT (PBA)

**MARINUS (POS)**

A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF GANAXOLONE AS ADJUNCTIVE THERAPY FOR ADULTS WITH THE DRUG-RESISTANT PARTIAL-ONSET SEIZURES FOLLOWED BY LONG-TERM OPEN-LABEL TREATMENT

**MERCK 8931-019 (PRODROMAL AD)**

A PHASE II/III RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOUBLE BLIND CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF MK 8931 IN SUBJECT WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (PRODROMAL AD)

**SANOFI LPS13567 (RELAPSING MULTIPLE SCLEROSIS)**

A PROSPECTIVE, SINGLE ARM, CLINICAL-SETTING STUDY TO DESCRIBE EFFICACY, TOLERABILITY AND CONVENIENCE OF TERIFLUNOMIDE TREATMENT USING PATIENT REPORTED OUTCOMES (PROs) IN RELAPSING MULTIPLE SCLEROSIS (RMS) PATIENTS

**SHIONOGI 1326V9235 (OIC)**

A RANDOMIZED DOUBLE-BLIND,PLACEBO-CONTROLLED,PARALLEL-GROUP,MULTICENTER,PHASE 3 STUDY TO EVALUATE THE LONG-TERM SAFETY OF NALDEMEDINE FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN SUBJECTS WITH NON-MALIGNANT CHRONIC PAIN RECEIVING OPIOID THERAPY

**CUBIST 5945-SOIC-12-05 (OIC)**

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE LONG- TERM SAFETY AND TOLERABILITY OF CB-5945 FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN ADULTS TAKING OPIOID THERAPY FOR CHRONIC NON-CANCER PAIN

**CUBIST 5945-SOIC-12-02 (OIC)**

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CB-5945 FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN ADULTS TAKING OPIOID THERAPY FOR CHRONIC NON-CANCER PAIN

**UCB N01358 (BRIVARACETAM PARTIAL ONSET SEIZURES)**

A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (> 16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES

**UCB N01379 (BRIVARACETAM PARTIAL ONSET SEIZURES)**

AN OPEN-LABEL,MULTICENTER,FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY

**PFIZER A0081105 (EPILEPSY PRIMARY GENERALIZED TONIC CLONIC SEIZURES)**

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC CLONIC SEIZURES

**ALLERGAN GMA-BTX-CM-10-001 (COMPEL / Botox)**

AN OPEN LABEL, MULTICENTER STUDY OF THE LONG TERM EFFICACY, SAFETY AND TOLERABILITY OF BOTOX (ONABOTULINUMTOXINA) FOR THE PROPHYLAXIS OF HEADACHES IN ADULT PATIENTS WITH CHRONIC MIGRAINE (THE COMPEL STUDY)

**ASTRAZENECA 12AST11894/A-12292 (OIC Burden of Illness)**

LONGITUDINAL STUDY OF PATIENTS WITH OPIOID-INDUCED CONSTIPATION

**MERCK 8931-017 (Alzheimer’s Disease)**

A RANDOMIZED, PLACEBO CONTROLLED, PARALLEL-GROUP, DOUBLE BLIND EFFICACY AND SAFETY TRIAL OF MK-8931 IN SUBJECTS MILD TO MODERATE ALZHEIMER’S DISEASE

**NOVARTIS CFTY720DUS09 (PREFERMS)**

 12-MONTH, PROSPECTIVE, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE PATIENT RETENTION OF FINGOLIMOD VS. APPROVED FIRST-LINE DISEASE MODIFYING THERAPIES IN ADULTS WHO ARE IN EARLY STAGES OF TREATMNET FOR RELAPSING REMITTING MULTIPLE SCLEROSIS (PREFERMS)

**UCB SP0980 (VIMPAT)**

A PROSPECTIVE,MULTINATIONAL, OPEN-LABEL, SINGLE-ARM, EXPLORATORY STUDY TO EVALUATE THE TOLERABLITY AND EFFICACY OF LACOSAMIDE WHEN ADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CHANNEL BLOCKING ANTIEPILEPTIC DRUG IN SUBJECTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURES

**PFIZER A0081106 (Pediatric Epilepsy)**

A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONT TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AND ADULT SUBJECTS 5 TO 65 YEARS OF AGE WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES

**SHIONOGI 1107V9221 (OIC)**

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY OF S-297995 FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN SUBJECTS WITH NON-MALIGNANT PAIN RECEIVING OPIOID THERAPY

**SEPRACOR 093-050 (Epilepsy)**

LONG-TERM ESLICARBAZEPINE ACETATE EXTENSION STUDY

**BIOGEN 101JC402 (JCV)**

JCV ANTIBODY PROGRAM IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS RECEIVING OR CONSIDERING TREATMENT WITH TYSABRI/STRATIFY -2

**TEVA (COPAXONE)**

AN OPEN-LABEL, MULTICENTER STUDY EVALUATING PATIENT INJECTION SATISFACTION WITH TWO FORMULATIONS OF COPAXONE FOR SUBCUTANEOUS INJECTION UTILIZING AUTOJECT 2 DEVICES

**NOVARTIS CFTY720DUS01 (EPOC)**

A 6 MONTH, RANDOMIZED, ACTIVE COMPARATOR, OPEN-LABEL, MULTI-CENTER, STUDY TO EVALUATE PATIENT OUTCOMES, SAFETY AND TOLERABILITY OF FINGOLIMOD/DAY IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHO ARE CANDIDATES FOR MS THERAPY CHANGE FROM PREVIOUS DISEASE MODIFYING THERAPY (EPOC)

**CHELSEA THERAPEUTICS NOH306 (PARKINSON’S)**

A MULTI CENTER,DOUBLE-BLIND,RANDOMIZED,PARALLEL-GROUP,PLACEBO-CONTROLLED STUDY TO ASSESS THE CLINICAL EFFECT OF DROXIDOPA IN THE TREATMENT OF SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH PARKINSON’S DISEASE

**ASTRAZENECA D3820C00008 (OIC)**

AN OPEN-LABEL 52-WEEK STUDY TO ASSESS THE LONG-TERM SAFETY OF NKTR-118 IN OPIOID-INDUCED CONSTIPATION (OIC) IN PATIENTS WITH NON-CANCER-RELATED PAIN

**SEPRACOR 093-046 (Epilepsy)**

11/2010-AUG 2012

DOUBLE-BLIND, RANDOMIZED, HISTORICAL CONTROL STUDY OF THE SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE MONOTHERAPY IN SUBJECTS WITH PARTIAL EPILEPSY NOT WELL CONTROLLED BY CURRENT ANTIEPILEPTIC DRUGS

**SP0954 (VIMPAT) EPILEPSY PARTIAL ONSET SEIZURES**

07/2010-11/2012

AN OPEN-LABEL, MULTICENTER, MULTINATIONAL STUDY OF LACOSIMIDE AS FIRST ADD-ON ANTIEPILEPTIC DRUG (AED) TREATMENT IN SUBJECTS WITH PARTIAL-ONSET SEIZURES